WHERE OTHERS SEE COMPLEXITY,
MALLINCKRODT SEES VALUE FOR PATIENTS.
For nearly 150 years, the Mallinckrodt name has represented quality products, business integrity, and service – to patients, customers
and the communities in which we live and work. Now once again an independent
global specialty pharmaceutical company, at Mallinckrodt Pharmaceuticals we continue to apply our unique
strengths, experience and expertise to bring products to the market that
provide enormous value for physicians and the patients we jointly serve.
The common thread critical to our past and
future success is that strong ability to master and manage complexity. Simply
put – we strive to make the complex simple.
Our core strengths provide the catalysts for
future success, including the
acquisition and management of highly regulated raw materials; deep regulatory knowledge;
distinctive manufacturing and logistics skills where vertical integration is an
advantage; expertise in specialized chemistry, development and formulation; and
global commercial reach.
Nearly a century and a half ago, Gustav, Otto and Edward Mallinckrodt founded G. Mallinckrodt
and Company in 1867. The company has grown and established many
vital milestones along the way. What set us apart then also sets us apart today
– our core values of quality, integrity
Recent key developments have fueled our
company’s growth, including the acquisition of important brands that have
expanded our commercial platforms. We’ve also secured U.S. Food and Drug
Administration approval of a dozen new products since 2010. We evaluate
additional opportunities with an eye to improving and expanding our portfolio
to bring value to all stakeholders. As we look to the future, we’ll continue to
implement strategies that will capitalize on the broad growth platforms we have
created with a strong portfolio of pain and central nervous system products for
office- and hospital-based physicians, and in rare disease therapeutic areas.
Mallinckrodt has a growing branded product
portfolio that is bringing innovative solutions to patients. Millions of
patients suffer each day from acute and chronic pain. Using our core strengths
in development, formulation and manufacturing, as well as through targeted
acquisitions, we provide a robust portfolio of analgesics to address pain both
in the hospital setting and at home. At the same time, Mallinckrodt is
committed to fighting opioid misuse and abuse; we advance diverse programs that
encourage and support appropriate use of pain medications.
Our autoimmune and rare diseases business provides
therapies to treat patients suffering from a variety of devastating and
difficult to treat brain, autoimmune and inflammatory illnesses, often for
individuals for whom other therapies provide unsatisfactory treatment outcomes.
Specialty therapeutic areas of focus include neurology, rheumatology, nephrology
The company is also one of the top 10 U.S.
generic pharmaceutical companies, based on prescriptions written in 2013, and
our specialty controlled substance generic products have formed Mallinckrodt’s
base business for decades. Our active pharmaceutical ingredients (APIs),
including narcotics, acetaminophen, stearates, phosphates and peptides, are
used in the manufacture of a variety of prescription drugs and other products.
Global Medical Imaging
Our medical imaging business helps aid diagnosis
of disease for millions of patients worldwide. The discovery of X-rays for
medical diagnosis in 1895 changed the world of medicine. Mallinckrodt
Pharmaceuticals remains at the forefront of these advances. Our experience
allows us to offer high-quality contrast agents, delivery systems and
radiopharmaceuticals essential to diagnostic imaging.
Our ability to manufacture complex products
and deliver them efficiently to our customers reflects our values of quality, integrity
Through the recent acquisition of Cadence Pharmaceuticals and Questcor Pharmaceuticals, Mallinckrodt has expanded its platform to better serve patients. Learn more about our recent acquisitions using the links below.